Monte Rosa Therapeutics, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Jul 16, 2026+2.7
Trials
- GLUEMonte Rosa Therapeutics, Inc13Calm
Study of Oral MRT-2359 in Selected Cancer Patients
Running, no new patientsPhase 1/2174 patientsMain results: Dec 2026 - GLUEMonte Rosa Therapeutics, Inc3Calm
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Signing up patientsPhase 225 patientsMain results: Oct 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
20 sales (4 not pre-planned) · 0 purchases
- Bowen MatthewPrincipal Accounting Officer · Oct 5, 2026Sold 13 sharesabout $137 · not pre-planned
- Warmuth MarkusPresident & CEO · Jul 16, 2026Sold 9,500 sharesabout $220 thousand · not pre-planned
- Champoux JenniferChief Operating Officer · Jul 15, 2026Sold 4,351 sharesabout $102 thousand · pre-planned
- Townson SharonChief Scientific Officer · Jul 6, 2026Sold 5,600 sharesabout $130 thousand · pre-planned
- Townson SharonChief Scientific Officer · Jul 6, 2026Sold 400 sharesabout $10 thousand · pre-planned
- Janku FilipChief Medical Officer · Jun 30, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.